Adjunctive Treatment of Chronic Migraine Using an Oral Dental Device

NCT ID: NCT04871581

Last Updated: 2021-05-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-01

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single blinding study comparing FDA cleared device for prevention of medically diagnosed migraine pain to placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In order to determine if nocturnal jaw clenching can be an influence on chronic migraine pain, the FDA cleared "NTI" (Nociceptive Trigeminal Inhibition) device with the Indications for Use of "for prophylactic treatment of medically diagnosed migraine pain" was compared to a similar device that had no influence on jaw clenching.The HIT-6 (Headache Impact Test) score was selected as the outcome measure, as the goal was to focus on improving disability in sufferer's lives, as in chronic migraine, changes in headache days may not be as helpful as improving disability.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Migraine, Headache

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Single blinded cross-over study
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants
Participants were advised that two different designs of device were being compared to each other.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Device

Subjects receiving the FDA-cleared device

Group Type ACTIVE_COMPARATOR

NTI-tss

Intervention Type DEVICE

FDA cleared device for prophylactic treatment of medically diagnosed migraine pain

Placebo

Subjects receiving the sham device

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DEVICE

Similar to Device, but having no influence on clenching intensity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NTI-tss

FDA cleared device for prophylactic treatment of medically diagnosed migraine pain

Intervention Type DEVICE

Placebo

Similar to Device, but having no influence on clenching intensity

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ChairsideSplint.com

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boyd James

Solana Beach, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol. 2000 Jun;13(3):277-83. doi: 10.1097/00019052-200006000-00008.

Reference Type BACKGROUND
PMID: 10871251 (View on PubMed)

Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep. 2001 Dec;5(6):529-36. doi: 10.1007/s11916-001-0070-6.

Reference Type BACKGROUND
PMID: 11676887 (View on PubMed)

Rozen TD. Migraine prevention: what patients want from medication and their physicians (a headache specialty clinic perspective). Headache. 2006 May;46(5):750-3. doi: 10.1111/j.1526-4610.2006.00429.x.

Reference Type BACKGROUND
PMID: 16643577 (View on PubMed)

Goadsby PJ. Migraine pathophysiology. Headache. 2005 Apr;45 Suppl 1:S14-24. doi: 10.1111/j.1526-4610.2005.4501003.x.

Reference Type BACKGROUND
PMID: 15833086 (View on PubMed)

Graff-Radford SB, Newman AC. The role of temporomandibular disorders and cervical dysfunction in tension-type headache. Curr Pain Headache Rep. 2002 Oct;6(5):387-91. doi: 10.1007/s11916-002-0081-y.

Reference Type BACKGROUND
PMID: 12207852 (View on PubMed)

Steele JG, Lamey PJ, Sharkey SW, Smith GM. Occlusal abnormalities, pericranial muscle and joint tenderness and tooth wear in a group of migraine patients. J Oral Rehabil. 1991 Sep;18(5):453-8. doi: 10.1111/j.1365-2842.1991.tb01690.x.

Reference Type BACKGROUND
PMID: 1800695 (View on PubMed)

Lamey PJ, Barclay SC. Clinical effectiveness of occlusal splint therapy in patients with classical migraine. Scott Med J. 1987 Feb;32(1):11-2. doi: 10.1177/003693308703200105.

Reference Type BACKGROUND
PMID: 3563468 (View on PubMed)

Clark GT, Sakai S, Merrill R, Flack VF, McArthur D, McCreary C. Waking and sleeping temporalis EMG levels in tension-type headache patients. J Orofac Pain. 1997 Fall;11(4):298-306.

Reference Type BACKGROUND
PMID: 9656905 (View on PubMed)

Graff-Radford SB. Oromandibular disorders and headache. A critical appraisal. Neurol Clin. 1990 Nov;8(4):929-45.

Reference Type BACKGROUND
PMID: 2259320 (View on PubMed)

Yap AU, Chua AP. Sleep bruxism: Current knowledge and contemporary management. J Conserv Dent. 2016 Sep-Oct;19(5):383-9. doi: 10.4103/0972-0707.190007.

Reference Type BACKGROUND
PMID: 27656052 (View on PubMed)

Burnett CA, Fartash L, Murray B, Lamey PJ. Masseter and temporalis muscle EMG levels and bite force in migraineurs. Headache. 2000 Nov-Dec;40(10):813-7. doi: 10.1046/j.1526-4610.2000.00147.x.

Reference Type BACKGROUND
PMID: 11135025 (View on PubMed)

Chandu A, Suvinen TI, Reade PC, Borromeo GL. The effect of an interocclusal appliance on bite force and masseter electromyography in asymptomatic subjects and patients with temporomandibular pain and dysfunction. J Oral Rehabil. 2004 Jun;31(6):530-7. doi: 10.1111/j.1365-2842.2004.01377.x.

Reference Type BACKGROUND
PMID: 15189309 (View on PubMed)

Nishigawa K, Bando E, Nakano M. Quantitative study of bite force during sleep associated bruxism. J Oral Rehabil. 2001 May;28(5):485-91. doi: 10.1046/j.1365-2842.2001.00692.x.

Reference Type BACKGROUND
PMID: 11380790 (View on PubMed)

Castillo J, Munoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache. 1999 Mar;39(3):190-6. doi: 10.1046/j.1526-4610.1999.3903190.x.

Reference Type RESULT
PMID: 15613213 (View on PubMed)

Blumenfeld AM, Boyd JP. Adjunctive treatment of chronic migraine using an oral dental device: overview and results of a randomized placebo-controlled crossover study. BMC Neurol. 2022 Mar 4;22(1):72. doi: 10.1186/s12883-022-02591-8.

Reference Type DERIVED
PMID: 35246048 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NTI v Placebo

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Migraine Prevention Using ActiPatch
NCT03166046 COMPLETED NA